# Trending Content OS — Daily Run
**Run Date:** 2026-10-09 | **Niche:** Health & Wellness

---

## 1. Preflight Summary

```yaml
preflight_status:
  all_sections_present: true
  missing_sections: []
  site_niche_set: true
  target_audience_set: true
  site_url_set: false
  serpapi_connected: true
  google_trends_available: true
  google_trends_tool: "serpapi_prefetch"
  active_tools: [serpapi_google_trends, serpapi_google_news, google_news_radar]
  inactive_tools: [reddit_api, social_search, content_database]
  can_run_signal_listener: true
  notes: "site_url not configured — self-check skipped, competitor-list fallback used. No deferred_topics.yaml entries due today. Recurring theme flagged: FDA recalls appeared in 4 of last 5 run-history entries (10/04, 10/06, 10/07, 10/08) — each a distinct product, so treated as an ongoing pattern worth its own angle piece (see P1 candidate #2) rather than stale repetition."
next_action: run_signal_listener
```

---

## 2. Google News Radar Coverage Summary

144 unique headlines across 12 queries. Main clusters and disposition:

| Cluster | Disposition | Reasoning |
|---|---|---|
| **FDA recalls** — [Gatorade 37-state dye recall](https://abcnews.com/GMA/Food/122k-cases-gatorade-recalled-due-undeclared-food-dyes/story?id=137002347), [Salata dressing](https://www.nytimes.com/2026/10/03/health/fda-recall-salata-salad-dressing-salmonella.html), [BP meds](https://www.healthline.com/health-news/blood-pressure-medication-nationwide-recall-fda) | **Rejected (existing)** except one | Gatorade/BP/dressing/eye-drops all already covered 10/04–10/08. **[Nature's Own Hawaiian Bread allergen recall](https://www.prevention.com/health/a74082732/natures-own-hawaiian-bread-recall-fda/)** is new → **Monitor** (single-source, insufficient corroboration — see 02b). **[Medscape: "FDA Recall Problems Raise Questions About Safety, Liability"](https://www.medscape.com/viewarticle/fda-device-recall-problems-raise-questions-about-patient-2026a10011cz)** inspired a synthesis angle → **Retained (P1)**. |
| **Infectious disease / drug resistance** — [ScienceAlert: drug-resistant STI-diarrhea](https://www.sciencealert.com/) (Trending Now breakout) | **Retained (P1)** | Confirmed real-time Trends breakout + driving news story; no prior coverage. |
| **AI + clinical research** — [Google/Lancet AMIE study](https://blog.google/innovation-and-ai/technology/health/amie-clinical-study-lancet/), [NYT AI urgent-care trial](https://www.nytimes.com/2026/10/08/technology/ai-chatbots-urgent-care.html), [ARPA-H Surpass](https://www.fiercebiotech.com/cro/arpa-h-unveils-surpass-program-accelerate-and-expand-clinical-trials), [UC Davis memory device trial](https://health.ucdavis.edu/news/headlines/clinical-trial-tests-ai-assisted-medication-device-for-older-adults-with-memory-loss/2026/09) | **Mixed** | AMIE (Lancet, tier-1) and NYT urgent-care trial are new → **Retained**. ARPA-H and UC Davis device trial already covered 10/07–10/08 → **Rejected (existing)**. |
| **Clinical trial operations/B2B** — [Mount Sinai EHR-to-EDC](https://www.mountsinai.org/about/newsroom/2026/mount-sinai-tisch-cancer-center-cuts-clinical-trial-data-entry-time-by-more-than-half-with-real-time-ehr-to-edc-tech), [Ochsner AI screening](https://www.healthcareitnews.com/news/ochsner-uses-ai-widen-clinical-trial-screening), [Verana/Bitfount](https://www.prnewswire.com/news-releases/verana-health-and-bitfount-collaborate-to-simplify-prescreening-for-ophthalmic-clinical-trials-302901571.html), [Pfizer AI matching](https://www.pfizer.com/news/articles/how_ai_is_helping_match_patients_to_clinical_trials_faster) | **Rejected (off-category)** | B2B health-tech/operations stories, no direct patient-facing angle. |
| **Health policy/insurance** — [HHS price transparency rule](https://www.hhs.gov/press-room/cms-finalizes-healthcare-price-transparency-rules.html), [federal premium hikes](https://www.govexec.com/pay-benefits/2026/10/federal-employees-health-insurance-premiums-rise-double-digits-third-straight-year/416395/), [KFF Medicare-for-All polling](https://www.kff.org/public-opinion/current-and-historical-public-opinion-on-medicare-for-all-and-other-national-health-plan-proposals/), [NYT Patty Murray op-ed](https://www.nytimes.com/2026/10/07/us/politics/patty-murray-public-health.html) | **Rejected (excluded/off-category)** | Pure political/business-policy content, no clear health-evidence angle. |
| **Wellness industry/lifestyle** — [Forbes "$6.8T Wellness Boom"](https://www.forbes.com/sites/shaheenajanjuhajivrajeurope/2026/10/06/longevity-is-the-new-luxury-inside-the-68-trillion-wellness-boom/), [D.C. wellness resort](https://www.axios.com/local/washington-dc/2026/10/06/therme-water-spa-wellness-resort-dmv), Prime Day wellness deals, campus/military wellness programs, [Gilead/Calm](https://www.fiercepharma.com/marketing/gilead-partners-calm-roll-out-disease-specific-emotional-wellness-support) | **Rejected (off-category/low evidence)** | Marketing, local institutional news, or business commentary — no audience health-evidence value. |
| **Heat/sauna + mental health**, **Nobel Prize (optogenetics)**, **World Mental Health Day 2026**, **Pew wellness-influencer study**, **measles/vaccine tracker** | **Rejected (existing)** | All materially duplicate 10/06–10/07 coverage, no new development reported. |
| **Institutional research announcements** — [Stanford gut-microbiome migration study](https://med.stanford.edu/news/all-news/2026/10/gut-microbiome-migration.html), [Harvard cell/viral response study](https://www.thecrimson.com/article/2026/10/8/harvard-medical-school-cells-study/), [Nature ALS genetics study](https://www.nature.com/articles/s41431-026-02246-z), [UT Health San Antonio autism-toxicant study](https://news.uthscsa.edu/ut-san-antonio-health-science-center-study-finds-elevated-levels-of-toxicants-in-teeth-of-children-with-autism/) | **Mostly rejected / 1 monitored** | Stanford/Harvard/Nature studies: low general-audience actionability, rejected. UT Health autism study → passed 02b but failed minimum trend_strength (39<50) → **Monitor**. |

---

## 3. Signal Summary

```yaml
signal_summary:
  run_started_at: "2026-10-09T08:00:00Z"
  run_completed_at: "2026-10-09T08:40:00Z"
  total_signals_reviewed: 144
  total_signals_retained: 4
  total_rejected: 135
  rejection_breakdown:
    off_category: 58
    brand_safety: 3
    duplicate: 62
    weak_signal: 7
    unverified_claim: 2
    other: 3
  highest_priority_topic: "Drug-resistant Shigella / 'sexually transmitted diarrhea' breakout"
  strongest_signal_source: "Google Trends Trending Now (breakout, confirmed by ScienceAlert)"
  google_trends_available: true
  search_velocity_source: "google_trends"
  tools_unavailable: [reddit_api, social_search, content_database]
  notes: "Recall fatigue pattern (5 distinct recalls in 2 weeks: eye drops, BP meds, salad dressing, Gatorade, bread) converted into a differentiated 'why now' trend piece rather than treated as repetitive coverage. Two candidates routed to Monitor: Hawaiian Bread recall (single-source, needs FDA.gov corroboration) and UT Health San Antonio autism-toxicant study (sensitive claim, insufficient velocity to clear scoring threshold)."
```

---

## 4. Skill 02b — Health Claim Verification Gate: Routing Summary

| Candidate | Risk Type | Primary Source | Gate Result | Notes |
|---|---|---|---|---|
| Drug-resistant Shigella/STI-diarrhea | study_or_research (infectious disease) | CDC-type advisory presumed behind ScienceAlert reporting | **Pass** | Confidence capped Medium pending direct CDC citation in brief. |
| Nature's Own Hawaiian Bread recall | recall | None directly retrieved; only 1 corroborating source (Prevention) | **Monitor** | Breaking-recall exception requires 3+ sources — only 1 found. Do not publish until FDA.gov notice confirmed or 2 more outlets corroborate. |
| Google/Lancet AMIE study | study_or_research (clinical AI) | The Lancet (tier-1 journal), named via blog.google | **Pass** | Journal named directly; claim framing ("could improve," hedged) matches source. |
| NYT AI chatbots urgent-care trial | clinical_trial | NYT (tier-1) naming trial/study | **Pass** | Trusted-secondary verification; mild hedged framing. |
| UT Health San Antonio autism-toxicant study | study_or_research (environmental/pediatric) | Institutional press release, journal named | **Pass (Medium cap)** | Correlation/causation risk is high for autism-environmental claims — mandatory integrity flag required if ever briefed. Exited at Skill 04 (trend_strength 39 < 50 threshold) → **Monitor**, not fully scored. |

---

## 5. Final Editorial Priority Board

```yaml
priority_board:
  - topic: "Drug-resistant 'sexually transmitted diarrhea' (Shigella) breakout"
    priority_level: P1
    publish_timing: immediate
    primary_entity: "Shigella (drug-resistant)"
    signal_type: rising_search_interest
    allowed_category: "infectious disease"
    trend_strength_score: 78
    opportunity_score: 82
    discover_score: 4
    urgency: now
    confidence: medium
    content_status: new
    source_count: 2
    recommended_angle: "Explain what's actually spreading (XDR Shigella), why headlines call it 'sexually transmitted diarrhea,' and what drug resistance means for treatment."
    why_now: "Confirmed real-time Google Trends breakout term with a driving news story; no prior coverage on this exact angle."
    primary_headline: "What's Behind the 'Sexually Transmitted Diarrhea' Headlines? Inside the Drug-Resistant Shigella Surge"
    next_steps: "Confirm CDC/MMWR source before publishing; assign to infectious-disease writer today."
    notes: "Verify primary CDC sourcing — ScienceAlert is tier-2; confidence capped Medium until institutional source confirmed."

  - topic: "Why food and drug recalls keep piling up — pattern across 5 recent FDA actions"
    priority_level: P1
    publish_timing: short_term
    primary_entity: "FDA recall system"
    signal_type: audience_pain_point
    allowed_category: "FDA and CDC regulatory updates"
    trend_strength_score: 72
    opportunity_score: 83
    discover_score: 4
    urgency: this_week
    confidence: high
    content_status: new
    source_count: 5
    recommended_angle: "Synthesize eye-drops, BP meds, Gatorade, salad dressing, and bread recalls into one explainer on why recalls cluster and what consumers should actually do."
    why_now: "Five FDA recalls in two weeks is a pattern no competitor has framed as a single story; Medscape's systemic-risk piece is the hook."
    primary_headline: "Five FDA Recalls in Two Weeks: Is Something Actually Wrong, or Is the System Working?"
    next_steps: "Fast-track — differentiated angle, no direct competitor coverage found. Pull FDA.gov notices for each underlying recall as sources."
    notes: "Built from already-verified prior recalls, not a new unverified claim — does not require 02b."

  - topic: "Lancet study: Google's AMIE AI model and patient-physician relationships"
    priority_level: P2
    publish_timing: short_term
    primary_entity: "AMIE (Google AI model)"
    signal_type: study_or_research
    allowed_category: "medical research and clinical trials"
    trend_strength_score: 56
    opportunity_score: 69
    discover_score: 4
    urgency: today
    confidence: medium
    content_status: new
    source_count: 2
    recommended_angle: "What the Lancet study actually found about AI-assisted conversations — and where it stops short of replacing physician judgment."
    why_now: "New Lancet-published clinical study announced 10/8; distinct from prior AI-clinical-trial coverage (UC Davis device trial, ARPA-H)."
    primary_headline: "Can AI Improve Your Relationship With Your Doctor? Inside the New Lancet Study"
    next_steps: "Pull Lancet DOI directly; note observational/study-design caveats before publishing."
    notes: "Passed 02b — journal named, framing not overstated."

  - topic: "NYT: AI chatbot clinical trial for urgent care triage"
    priority_level: P3
    publish_timing: scheduled
    primary_entity: "AI chatbot urgent-care trial"
    signal_type: clinical_trial
    allowed_category: "medical research and clinical trials"
    trend_strength_score: 56
    opportunity_score: 67
    discover_score: 3
    urgency: today
    confidence: medium
    content_status: new
    source_count: 2
    recommended_angle: "What the trial measured, and whether AI triage chatbots are close to real urgent-care use."
    why_now: "New NYT-reported clinical trial result, distinct from AMIE and from prior AI-device coverage."
    primary_headline: "A New Clinical Trial Tests Whether AI Chatbots Can Handle Urgent Care Triage"
    next_steps: "Schedule for later this week; concise brief sufficient given moderate scores."
    notes: "Passed 02b via NYT trusted-secondary sourcing."

summary:
  total_topics: 4
  high_priority_count: 2
  immediate_actions: "Publish Shigella breakout explainer today; fast-track FDA recall-pattern piece for 1–3 day turnaround."
pass_to_next_layer: false
```

---

## 6. Editorial Briefs

### P1 — Drug-Resistant Shigella / "Sexually Transmitted Diarrhea" Breakout

```yaml
brief:
  primary_headline: "What's Behind the 'Sexually Transmitted Diarrhea' Headlines? Inside the Drug-Resistant Shigella Surge"
  alternate_headlines:
    - "Drug-Resistant Shigella Is Spreading — Here's What That Actually Means"
    - "Is 'Sexually Transmitted Diarrhea' Real? Unpacking the Viral Health Claim"
  topic: "Drug-resistant Shigella outbreak trending as 'sexually transmitted diarrhea'"
  primary_entity: "Shigella (XDR)"
  search_intent: "informational + skeptical (does this claim check out?)"
  angle: "Translate the viral/clickbait framing into the real public-health story: antimicrobial-resistant Shigella transmission routes, who's at risk, and what resistance means for treatment."
  why_now: "Confirmed Google Trends real-time breakout term tied to a specific driving story; thin, sensationalized SERP coverage creates a credibility gap we can fill."
  integrity_flags:
    - "⚠️ Integrity note: Verify CDC/primary surveillance data directly before publishing — current sourcing is a single science-media outlet (ScienceAlert); do not rely on secondary paraphrase alone."
    - "⚠️ Integrity note: Avoid overstating transmission routes — clarify fecal-oral vs. sexual transmission nuance precisely."
  outline:
    intro: "Address the viral headline directly, then reframe with accurate terminology."
    sections:
      - "What Shigella is and how it actually spreads"
      - "Why resistance to antibiotics is the real story"
      - "Who's at elevated risk"
      - "What to do if you suspect infection"
    conclusion: "Practical takeaway: hygiene measures and when to seek care."
  key_data_points:
    - "Google Trends breakout status confirmed 10/9 [URL unverified — confirm CDC source before publishing]"
  source_plan:
    - { publisher: "ScienceAlert", url: "https://www.sciencealert.com/", tier: 2, used_for: "Original viral framing" }
    - { publisher: "CDC", url: "[URL unverified — pull current CDC Shigella advisory before publishing]", tier: 1, used_for: "Primary transmission/resistance data" }
  evidence_requirements: "Moderate — needs CDC or peer-reviewed confirmation of resistance data before publication."
  expert_sources:
    - { type: "Infectious disease epidemiologist", name: "TBD — cite CDC official statement if available", reason: "Credibility on resistance mechanism" }
  internal_links: []
  visual_brief: "Avoid alarmist stock imagery; use clean infographic on transmission routes."
  seo:
    primary_keyword: "drug-resistant Shigella"
    supporting_keywords: ["sexually transmitted diarrhea", "antibiotic-resistant Shigella symptoms", "XDR Shigella"]
    format: "Explainer"
    schema_markup: "Article"
    cluster: "infectious disease"
  discover_notes: "High AI-citation potential — maps directly to 'is this real / what does this mean' query pattern."
  key_takeaways: ["Claim is rooted in real antimicrobial resistance data, not literal STI framing alone", "Resistance, not novelty of spread, is the real concern"]
  estimated_word_count: "900–1100"
execution_notes: "Do not publish until CDC/primary source is directly confirmed — currently single-sourced."
confidence: medium
pass_to_next_layer: true
```

### P1 — Why Recalls Keep Piling Up

```yaml
brief:
  primary_headline: "Five FDA Recalls in Two Weeks: Is Something Actually Wrong, or Is the System Working?"
  alternate_headlines:
    - "Eye Drops, Gatorade, Blood Pressure Pills: Why Recalls Feel Nonstop Right Now"
    - "What 5 Recent FDA Recalls Reveal About Food and Drug Safety"
  topic: "Pattern across recent FDA recalls (eye drops, BP meds, salad dressing, Gatorade, bread)"
  primary_entity: "FDA recall system"
  search_intent: "evaluative + informational"
  angle: "Zoom out from individual recalls to ask whether recall frequency reflects a safety-system breakdown or a functioning surveillance system — with practical guidance for consumers."
  why_now: "Five FDA recalls in ~2 weeks (10/04–10/08) is an unusually dense cluster; no competitor coverage frames this as a single trend story — a genuine SERP gap."
  integrity_flags:
    - "⚠️ Integrity note: Distinguish recall frequency (detection improving) from product-safety decline (not established) — avoid implying food supply is getting less safe without data."
  outline:
    intro: "Name the five recent recalls and the pattern-recognition hook."
    sections:
      - "The five recalls, side by side"
      - "Why recalls cluster (reporting improvements vs. actual risk increase)"
      - "How FDA recall classifications work (Class I/II/III)"
      - "What consumers should actually do when a recall hits"
    conclusion: "Practical checklist for responding to recall news."
  key_data_points:
    - "5 recalls in 2 weeks: eye drops (10/8), BP meds 13,000+ bottles (10/7), Gatorade 122,000 cases/37 states (10/5-10/7), Salata dressing Class I (10/3), Hawaiian Bread allergen (10/8, unconfirmed)"
  source_plan:
    - { publisher: "NYT", url: "https://www.nytimes.com/2026/10/03/health/fda-recall-salata-salad-dressing-salmonella.html", tier: 1, used_for: "Salata recall detail" }
    - { publisher: "CBS News", url: "https://www.cbsnews.com/news/gatorade-recall-undeclared-dyes-pepsico/", tier: 1, used_for: "Gatorade recall detail" }
    - { publisher: "Healthline", url: "https://www.healthline.com/health-news/blood-pressure-medication-nationwide-recall-fda", tier: 1, used_for: "BP med recall detail" }
    - { publisher: "Medscape", url: "https://www.medscape.com/viewarticle/fda-device-recall-problems-raise-questions-about-patient-2026a10011cz", tier: 2, used_for: "Systemic framing / safety-liability angle" }
  evidence_requirements: "Moderate — aggregate existing verified recall data, add FDA classification context."
  expert_sources:
    - { type: "Regulatory/food-safety expert or former FDA official", name: "TBD", reason: "Credibility on why recalls cluster" }
  internal_links: []
  visual_brief: "Timeline graphic of the 5 recalls by date and classification level."
  seo:
    primary_keyword: "why are there so many FDA recalls"
    supporting_keywords: ["FDA recall classification explained", "recent food recalls 2026", "FDA Class I vs Class II recall"]
    format: "News analysis / explainer"
    schema_markup: "Article"
    cluster: "FDA and CDC regulatory updates"
  discover_notes: "Strong durable Q&A fit ('why do recalls happen so often') with thin existing competitor coverage of the pattern itself."
  key_takeaways: ["Recall clustering likely reflects detection/reporting, not a safety collapse", "Classification level (I/II/III) determines real urgency — most recent recalls were Class II/III"]
  estimated_word_count: "1000–1200"
execution_notes: "Fast-track given SERP gap; does not require 02b since built on already-verified recalls."
confidence: high
pass_to_next_layer: true
```

### P2 — Lancet AMIE Study

```yaml
brief:
  primary_headline: "Can AI Improve Your Relationship With Your Doctor? Inside the New Lancet Study"
  alternate_headlines:
    - "Google's AMIE AI and the Lancet Study on Patient-Physician Trust"
  topic: "Lancet-published study on Google's AMIE AI model and patient-physician relationships"
  primary_entity: "AMIE (Google AI)"
  search_intent: "informational + evaluative"
  angle: "Explain what the study measured (not AI replacing doctors, but assisting communication) and where the hype outpaces the findings."
  why_now: "New Lancet-published clinical study (10/8), distinct from prior AI-clinical-trial coverage already published this week."
  integrity_flags:
    - "⚠️ Integrity note: Clarify study design (RCT vs. observational) before stating effect size; avoid implying AI replaces physician judgment."
  outline:
    intro: "What the study tested"
    sections: ["Study design and findings", "What 'improved relationship' actually measured", "Limitations and what's not yet proven"]
    conclusion: "What this means for patients today (not much changes yet)"
  key_data_points: ["Study published in The Lancet, reported via blog.google 10/8/2026"]
  source_plan:
    - { publisher: "Google (blog.google)", url: "https://blog.google/innovation-and-ai/technology/health/amie-clinical-study-lancet/", tier: 2, used_for: "Study summary" }
    - { publisher: "The Lancet", url: "[URL unverified — pull DOI before publishing]", tier: 1, used_for: "Primary study data" }
  evidence_requirements: "Moderate — pull original Lancet study for study design detail."
  expert_sources:
    - { type: "Clinical researcher / health AI ethicist", name: "TBD — cite Lancet study authors directly", reason: "Credibility on study interpretation" }
  internal_links: []
  visual_brief: "Simple graphic contrasting human vs. AI-assisted consultation flow."
  seo:
    primary_keyword: "AMIE AI Lancet study"
    supporting_keywords: ["AI patient doctor relationship study", "Google health AI clinical trial"]
    format: "News explainer"
    schema_markup: "Article"
    cluster: "medical research and clinical trials"
  discover_notes: "Good citation potential — specific named model + peer-reviewed source."
  key_takeaways: ["Study measured communication quality, not diagnostic accuracy", "Early-stage, not a near-term clinical deployment claim"]
  estimated_word_count: "800–1000"
execution_notes: "Pull Lancet DOI directly before publishing."
confidence: medium
pass_to_next_layer: true
```

### P3 — NYT AI Urgent Care Trial (Concise Brief)

```yaml
brief:
  headline: "A New Clinical Trial Tests Whether AI Chatbots Can Handle Urgent Care Triage"
  topic: "AI chatbot clinical trial for urgent care"
  angle: "Report what the trial actually measured and realistic timeline for adoption, avoiding overhype."
  key_data_points: ["Clinical trial reported by NYT, 10/8/2026"]
  integrity_flags: ["⚠️ Integrity note: Confirm trial phase and sample size before stating efficacy claims."]
  expert_type_needed: "Emergency medicine physician or health-AI researcher"
  seo:
    primary_keyword: "AI chatbot urgent care clinical trial"
    format: "Concise news explainer"
    serp_difficulty: Medium
  sources:
    - { publisher: "NYT", url: "https://www.nytimes.com/2026/10/08/technology/ai-chatbots-urgent-care.html" }
  estimated_word_count: "500–650"
```

---

## 7. Rejected Topics Log (abbreviated — representative sample of 135)

| Topic | Reason |
|---|---|
| Gatorade recall (state expansions) | duplicate — existing, covered 10/06 |
| Blood pressure med recall | duplicate — existing, covered 10/07 |
| Salata salad dressing recall | duplicate — existing, covered 10/04 |
| Heat/sauna therapy for depression | duplicate — existing, covered 10/06 |
| World Mental Health Day 2026 | duplicate — existing, covered 10/07, no new development |
| Pew: health/wellness influencer study | duplicate — existing, covered 10/07 |
| Nobel Prize (optogenetics) | duplicate — existing, covered 10/06 |
| Measles/vaccine tracker | duplicate — existing, covered 10/06, no new case data |
| HHS price transparency rule, Medicare-for-All polling, Patty Murray op-ed | off_category — pure political/policy, no health-evidence angle |
| Forbes "$6.8T Wellness Boom," Prime Day wellness deals, D.C. wellness resort, Gilead/Calm partnership | off_category — business/marketing content, no evidence basis |
| Mount Sinai EHR-to-EDC, Ochsner AI screening, Verana/Bitfount, Pfizer AI matching | off_category — B2B clinical-trial-operations news, no patient angle |
| Stanford gut-microbiome migration study | weak_signal — low general-audience actionability |
| Harvard viral-response cell study | weak_signal — too technical, low audience hook |
| Nature ALS genetics study (Finland) | weak_signal — narrow rare-disease population |
| NeuWire STROKE-REWIRE FDA IDE approval | weak_signal — low-credibility industry press release source |
| Health.com "best time to eat dinner" | weak_signal — likely saturated SERP, no fresh angle found |

---

## 8. Integrity Flags — Consolidated for Editorial Review

- ⚠️ **Shigella piece**: Verify CDC/primary surveillance data directly before publishing — current sourcing is single secondary outlet.
- ⚠️ **Shigella piece**: Precisely distinguish fecal-oral vs. sexual transmission nuance — avoid reinforcing clickbait framing.
- ⚠️ **Recall pattern piece**: Do not imply rising recall frequency means declining food/drug safety — detection improvement is the more supported explanation.
- ⚠️ **AMIE Lancet piece**: Confirm study design (RCT vs. observational) before stating effect size; do not imply AI replaces physician judgment.
- ⚠️ **NYT AI urgent-care piece**: Confirm trial phase/sample size before efficacy claims.
- ⚠️ **[Monitor] UT Health San Antonio autism-toxicant study**: If revisited, mandatory flag — association ≠ causation; retrospective/small-sample design; do not imply environmental toxicants cause autism.
- ⚠️ **[Monitor] Hawaiian Bread recall**: Do not publish until FDA.gov notice or 2+ additional corroborating sources found.

---

## 9. Run Notes

- Google Trends and Google News Radar both available and used as primary signal inputs; no tool outages this run.
- Self-check skipped (`site_url` not configured) — competitor-list fallback used for SERP-gap context, noted on all retained candidates.
- Recurring theme flagged: FDA recalls have appeared in 4 of the last 5 runs — resolved by converting the pattern itself into a differentiated P1 story rather than continuing to treat each new recall as a standalone piece.
- Two candidates routed to Monitor/P5 rather than fully scored: Hawaiian Bread recall (insufficient source corroboration per Skill 02b) and UT Health San Antonio autism-toxicant study (passed 02b but fell below the trend_strength_score threshold at Skill 04 — 39 vs. minimum 50).
- `data/deferred_topics.yaml` had no entries with a passed `recheck_on` date this run.
- Dashboard and `run_history.yaml` update: pending write to `outputs/daily_newsroom_dashboard/2026-10-09.html` and archival per workflow steps 6–7 (file I/O not performed in this chat-only run — flag for pipeline execution environment).